Your browser doesn't support javascript.
Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19.
Folgueira, Maria Dolores; Luczkowiak, Joanna; Lasala, Fátima; Pérez-Rivilla, Alfredo; Delgado, Rafael.
  • Folgueira MD; Department of Clinical Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital 12 de Octubre, imas12, Madrid, Spain; Department of Medicine, Complutense University of Madrid, School of Medicine, Madrid, Spain. Electronic address: mfolgueira@salud.madrid.org.
  • Luczkowiak J; Research Institute Hospital 12 de Octubre, imas12, Madrid, Spain.
  • Lasala F; Research Institute Hospital 12 de Octubre, imas12, Madrid, Spain.
  • Pérez-Rivilla A; Department of Clinical Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital 12 de Octubre, imas12, Madrid, Spain.
  • Delgado R; Department of Clinical Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital 12 de Octubre, imas12, Madrid, Spain; Department of Medicine, Complutense University of Madrid, School of Medicine, Madrid, Spain.
Clin Microbiol Infect ; 27(6): 886-891, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1101160
ABSTRACT

OBJECTIVES:

This study compares the infectivity of SARS-CoV-2 in respiratory samples from patients with mild COVID-19 with those from hospitalized patients with severe bilateral pneumonia. In severe COVID-19, we also analysed the presence of neutralizing activity in paired sera.

METHODS:

We performed cell cultures on 193 real-time reverse transcription polymerase chain reaction respiratory samples, positive for SARS-CoV-2, obtained from 189 patients at various times, from clinical diagnosis to follow-up. Eleven samples were obtained from asymptomatic individuals, 91 samples from 91 outpatients with mild forms of COVID-19 and 91 samples from 87 inpatients with severe pneumonia. In these patients, neutralizing activity was analysed in 30 paired sera collected after symptom onset >10 days.

RESULTS:

We detected a cytopathic effect (CPE) in 91/193 (47%) samples. Viral viability was maintained for up to 10 days in patients with mild COVID-19. In patients with severe COVID-19, the virus remained viable for up to 32 days after the onset of symptoms. Patients with severe COVID-19 presented infectious virus at a significantly higher rate in the samples with moderate to low viral load (cycle threshold value ≥ 26) 32/75 (43%) versus 14/63 (22%) for mild cases (p < 0.01). We observed a positive CPE despite the presence of clear neutralizing activity (NT50 > 11024 in 10% (3/30) of samples.

DISCUSSION:

Patients with severe COVID-19 might shed viable virus during prolonged periods of up to 4 weeks after symptom onset, even when presenting high cycle threshold values in their respiratory samples and despite having developed high neutralizing antibody titres.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Cultivation / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Prognostic study Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Cultivation / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Prognostic study Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article